1131 Participants Needed

Bimekizumab for Psoriatic Arthritis

(BE VITAL Trial)

Recruiting at 178 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: UCB Biopharma SRL
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 2 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing the safety and effectiveness of bimekizumab, a medication given as an injection under the skin. It is aimed at adults who have psoriatic arthritis, a condition that causes joint pain and swelling. Bimekizumab works by blocking proteins that cause inflammation, helping to reduce pain and swelling.

Who Is on the Research Team?

UC

UCB Cares

Principal Investigator

001 844 599 2273

Are You a Good Fit for This Trial?

This trial is for adults with active Psoriatic Arthritis who previously completed certain studies (PA0010 or PA0011) without withdrawal. Women must be postmenopausal, sterilized, or use effective contraception and not plan pregnancy during the study or within 20 weeks after the last dose.

Inclusion Criteria

I am postmenopausal, permanently sterilized, or I use effective birth control.
In the opinion of the Investigator, the subject is expected to benefit from participation in this Open-Label Extension study
You have participated in a previous study (PA0010 or PA0011) and did not meet the withdrawal criteria.

Exclusion Criteria

Subjects who meet any withdrawal criteria in PA0010 or PA0011. For any subject with an ongoing serious adverse event (SAE), or a history of serious infections (including hospitalizations) in the feeder studies, the Medical Monitor must be consulted prior to the subject's entry into PA0012, although the decision to enroll the subject remains with the Investigator
I do not plan to become pregnant during the study or within 5 months after the last dose.
I have had positive or unclear TB tests but have been checked or treated.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive bimekizumab subcutaneously for the treatment of psoriatic arthritis

140 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

72 weeks

Open-label extension

Participants may continue to receive bimekizumab to assess long-term safety and efficacy

Long-term

What Are the Treatments Tested in This Trial?

Interventions

  • Bimekizumab
Trial Overview The trial tests Bimekizumab's long-term safety and effectiveness when given as a subcutaneous injection to treat Psoriatic Arthritis. It aims to understand how well patients tolerate this medication over an extended period.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Bimekzumab dosage regimenExperimental Treatment1 Intervention
Subjects participating in the study will receive assigned bimekizumab dosage regimen during the Treatment Period.

Bimekizumab is already approved in European Union, United States for the following indications:

🇪🇺
Approved in European Union as Bimzelx for:
  • Moderate to severe plaque psoriasis
  • Active psoriatic arthritis
  • Non-radiographic axial spondyloarthritis
  • Active ankylosing spondylitis
🇺🇸
Approved in United States as Bimzelx for:
  • Moderate-to-severe plaque psoriasis
  • Active psoriatic arthritis
  • Non-radiographic axial spondyloarthritis
  • Active ankylosing spondylitis
  • Hidradenitis suppurativa

Find a Clinic Near You

Who Is Running the Clinical Trial?

UCB Biopharma SRL

Lead Sponsor

Trials
118
Recruited
23,200+

Jean-Christophe Tellier

UCB Biopharma SRL

Chief Executive Officer since 2015

MD from University of Reims Champagne-Ardenne, Rheumatology specialization from University of Paris V, Executive business programs at Harvard and INSEAD

Dr. Iris Loew-Friedrich

UCB Biopharma SRL

Chief Medical Officer since 2014

MD from University of Leuven, PhD in Medical Sciences from University of Leuven

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security